Publication

Differentiation of Induced Pluripotent Stem Cells Into Functional Oligodendrocytes

Czepiel, M., Balasubramaniyan, V., Schaafsma, W., Stancic, M., Mikkers, H., Huisman, C., Boddeke, E. & Copray, S., Jun-2011, In : Glia. 59, 6, p. 882-892 11 p.

Research output: Contribution to journalArticleAcademicpeer-review

  • Marcin Czepiel
  • Veerakumar Balasubramaniyan
  • Wandert Schaafsma
  • Mirjana Stancic
  • Harald Mikkers
  • Christian Huisman
  • Erik Boddeke
  • Sjef Copray

The technology to generate autologous pluripotent stem cells (iPS cells) from almost any somatic cell type has brought various cell replacement therapies within clinical research. Besides the challenge to optimize iPS protocols to appropriate safety and GMP levels, procedures need to be developed to differentiate iPS cells into specific fully differentiated and functional cell types for implantation purposes. In this article, we describe a protocol to differentiate mouse iPS cells into oligodendrocytes with the aim to investigate the feasibility of IPS stem cell-based therapy for demyelinating disorders, such as multiple sclerosis. Our protocol results in the generation of oligodendrocyte precursor cells (OPCs) that can develop into mature, myelinating oligodendrocytes in-vitro (co-culture with DRG neurons) as well as in-vivo (after implantation in the demyelinated corpus callosum of cuprizone-treated mice). We report the importance of complete purification of the iPS-derived OPC suspension to prevent the contamination with teratoma-forming iPS cells. (C) 2011 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)882-892
Number of pages11
JournalGlia
Volume59
Issue number6
Publication statusPublished - Jun-2011

    Keywords

  • pluripotency, remyelination, cell lineage, multiple sclerosis, SPINAL-CORD TRANSPLANTATION, HUMAN SOMATIC-CELLS, MULTIPLE-SCLEROSIS, AUTOIMMUNE ENCEPHALOMYELITIS, GLUTAMATE TRANSPORT, HUMAN FIBROBLASTS, DEFINED FACTORS, AXONAL LOSS, DISEASE, MODEL

ID: 5318044